Corcept Therapeutics Reports 37% Revenue Growth Amid Cushing’s Syndrome Demand Surge — Corcept Therapeutics Incorporated

Event summary

Corcept Therapeutics reported $761.4M in 2025 revenue, up 37% YoY, driven by record new prescriptions for Cushing’s syndrome treatments.
Fourth-quarter revenue hit $202.1M, up from $181.9M in Q4 2024, but net income fell to $24.3M from $30.7M due to operational disruptions.
FDA reviewing NDA for relacorilant in platinum-resistant ovarian cancer with PDUFA date of July 11, 2026.
Company plans Phase 3 trial for dazucorilant in ALS by mid-2026, following promising DAZALS study results.

The big picture

Corcept’s growth reflects increasing physician recognition of hypercortisolism, positioning it as a leader in cortisol modulation therapies. The company’s pipeline diversification into oncology and metabolic diseases could drive long-term value, but regulatory and operational hurdles remain critical. With $532.4M in cash reserves, Corcept has financial flexibility to navigate these challenges while pursuing multiple high-impact clinical programs.

What we're watching

Regulatory Approval: Whether the FDA will approve relacorilant for Cushing’s syndrome following the Complete Response Letter and the July 2026 PDUFA date for ovarian cancer indication.
Clinical Trial Results: The pace at which Corcept delivers data from ongoing trials, including MOMENTUM in resistant hypertension and MONARCH in MASH, which could expand market opportunities.
Operational Execution: How Corcept manages post-transition demand fulfillment after fourth-quarter disruptions at its new specialty pharmacy partner.